Keywords
COVID19
Systematic Review
How to Cite
Abstract
This systematic review aims to compare the drugs used for the treatment of COVID-19 in diagnosed and hospitalized patients. The search in the databases generated 97 references, which after the selection and eligibility process, 4 systematic reviews (SR) were selected and used in this narrative synthesis where their data were extracted. The AMSTAR 2 tool was used in the evaluation of methodological quality. The options were grouped according to the adopted interventions: Tocilizumab, Vitamin D, and Atorvastatin. It is concluded that the study has limitations in its methodology, and the results should be analyzed with caution. The presented options need to describe the standard treatment used. Tocilizumab appears to be the best choice in concurrent use with standard treatment.
References
ALMEIDA, P. R. L. et al. Effectiveness and safety of tocilizumab for COVID-19: a systematic review and meta-analysis of randomized clinical trials. Sao Paulo Medical Journal, v. 141, n. 2, p. 168–176, abr. 2023.
DIAS, V. M. DE C. H. et al. Orientações sobre diagnóstico, tratamento e isolamento de pacientes com COVID-19. Abr/Jun. v. 9, n. 2, p. 20, 13 abr. 2020.
FALAVIGNA, M. et al. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Revista Brasileira de Terapia Intensiva, v. 32, p. 166–196, 13 jul. 2020.
MS, M. DA SAÚDE. Coronavírus. Disponível em: <https://www.gov.br/saude/pt-br/coronavirus/coronavirus>. Acesso em: 20 set. 2023.
OPAS, O. P. D. SAÚDE.; OMS, O. M. D. SAÚDE. Histórico da pandemia de COVID-19 - OPAS/OMS | Organização Pan-Americana da Saúde. Disponível em: <https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19>. Acesso em: 20 set. 2023a.
OPAS, O. P. D. SAÚDE.; OMS, O. M. D. SAÚDE. Folha informativa sobre COVID-19 - OPAS/OMS | Organização Pan-Americana da Saúde. Disponível em: <https://www.paho.org/pt/covid19>. Acesso em: 20 set. 2023b.
OUZZANI, M. et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews, v. 5, n. 1, p. 210, 2016.
PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, 2021.
ROCHA, A. P. et al. Insufficient evidence for vitamin D use in COVID‐19: A rapid systematic review. International Journal of Clinical Practice, v. 75, n. 11, nov. 2021.
SHEA, B. J. et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, p. j4008, 21 set. 2017.
TLEYJEH, I. M. et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clinical Microbiology and Infection, v. 27, n. 8, p. 1076–1082, ago. 2021.
WHO, W. H. ORGANIZATION. WHO Coronavirus (COVID-19) Dashboard. Disponível em: <https://covid19.who.int>. Acesso em: 20 set. 2023.
XAVIER, D. P. et al. Effects of statin therapy in hospitalized adult COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. einstein (São Paulo), v. 21, p. eRW0351, 6 jun. 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Edgard Lindesay Neto, Alexandre Maslinkiewicz, Nicole Pischel
